Home > Cardiology > ISTH 2020 > What’s New in Anticoagulation > Lower embryopathy risk with DOAC versus VKA during pregnancy

Lower embryopathy risk with DOAC versus VKA during pregnancy

Presented By
Dr Jan Beyer-Westendorf, UNI-Klinikum Carl Gustav Carus Medizinische Klinik I, Germany
Conference
ISTH 2020
  Many patients receiving oral anticoagulation for venous thromboembolism (VTE) are in their reproductive years, but the potential for reproductive toxicity of direct oral anticoagulants (DOACs) in humans is not yet well established. A literature review evaluating pregnancy outcomes after DOAC exposure suggests DOACs have a lower risk of reproductive toxicity compared with vitamin-K antagonists (VKA) [1]. Dr Jan Beyer-Westendorf (UNI-Klinikum Carl Gustav Carus Medizinische Klinik I, Germany) pointed out that planned pregnancies in women on DOACs require a careful risk-benefit assessment, and that individualised decisions need to include patient perspective, preferences, and fears [1]. DOACs are small molecules that can cross the placenta. Previously, an increased transfer of dabigatran, rivaroxaban, and apixaban to the foetal site of the placenta was shown in a human pl...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on